Evidence map›Paper›PMID 32144393›Full record

ArticleCommunications biology2020

NDRG1 activates VEGF-A-induced angiogenesis through PLCγ1/ERK signaling in mouse vascular endothelial cells.

Kosuke Watari, Tomohiro Shibata, Hideaki Fujita, Ai Shinoda, Yuichi Murakami, Hideyuki Abe, Akihiko Kawahara, Hiroshi Ito, Jun Akiba, Shigeo Yoshida and 2 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Insight into the Regulation of NDRG1 Expression.International journal of molecular sciences · 2025
    Review
  7. Article
  8. New insights into the role of ubiquitination in angiogenesis (Review).International journal of molecular medicine · 2025
    Review
  9. Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors.Frontiers in cell and developmental biology · 2025
    Review
  10. Article
  11. Review
  12. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors.Journal of cancer research and clinical oncology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Role of the VEGF Family in Coronary Heart Disease.Frontiers in cardiovascular medicine · 2021
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Kosuke WatariDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Tomohiro ShibataDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Hideaki FujitaFaculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, 859-3243, Japan.
Ai ShinodaDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Yuichi MurakamiDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Hideyuki AbeDepartment of Diagnostic Pathology, Kurume University Hospital, Kurume, 830-0011, Japan.
Akihiko KawaharaDepartment of Diagnostic Pathology, Kurume University Hospital, Kurume, 830-0011, Japan.
Hiroshi ItoDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Jun AkibaDepartment of Diagnostic Pathology, Kurume University Hospital, Kurume, 830-0011, Japan.
Shigeo YoshidaDepartment of Ophthalmology, Kurume University School of Medicine, Kurume, 830-0011, Japan.
Michihiko KuwanoCancer Translational Research Center, St. Mary's Institute of Health Sciences, Kurume, 830-8543, Japan.
Mayumi OnoDepartment of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan. mono@phar.kyushu-u.ac.jp.
Kyushu University · JPKurume University Hospital · JPKurume University · JPNagasaki International University · JPSaga University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many diseases, including cancer, have been associated with impaired regulation of angiogenesis, of which vascular endothelial growth factor (VEGF)-A is a key regulator. Here, we test the contribution of N-myc downstream regulated gene 1 (NDRG1) to VEGF-A-induced angiogenesis in vascular endothelial cells (ECs). Ndrg1

Indexed as

Angiogenesis Inducing AgentsAnimalsBreast NeoplasmsCell Cycle ProteinsCell MovementCell ProliferationCells, CulturedCorneal NeovascularizationDisease Models, AnimalEndothelial CellsExtracellular Signal-Regulated MAP KinasesFemaleHumansIntracellular Signaling Peptides and ProteinsMaleMice, Inbred C57BLAngiogenesis Inducing AgentsCell Cycle ProteinsExtracellular Signal-Regulated MAP KinasesIntracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 ProteinPhospholipase C gammaPlcg1 protein, mouseVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID32144393
PMCPMC7060337
OpenAlexW3010299786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.